Concerning gender difference in IBS management, a study showed Alosetron, the 5-HT3 antagonist, to be more effective in improving urgency and diarrhea in IBS-D women than men [39] due to a mild difference in clearance of alosetron between women and men, with a slightly higher serum drug level in women. This evidence concerns the gene HTR3A and irritable bowel syndrome.